Group 225

BGI SENTIS Hereditary Cancer Screening

BGI’s hereditary risk screening cancer panels target genes previously linked to a predisposition of cancer. Panel selection was based on expert curation of scientific literature and other high quality resources, including formal medical guidelines.

Hereditary Breast and Ovarian Cancer Panel

BGI’s Hereditary Breast and Ovarian (HBOC) panel provides health providers and patients with information on 21 genes associated with Hereditary Breast and Ovarian Cancer (HBOC) based on recent scientific and clinical literature. BGI detects different alterations including germline SNV, Indels and CNV.

Comprehensive Hereditary Cancer Panel

BGI’s Comprehensive Hereditary Cancer Panel provides information on 62 genes associated with 18 different types of hereditary cancer such as breast cancer, ovarian cancer and colorectal cancer. BGI detects different alterations including germline SNV, Indels and CNV.

Group 226

BGI SENTIS Cancer Precision Medicine Discovery

BGI is dedicated to utilizing genomics in order to advance precision medicine for cancer. BGI’s next-generation sequencing assaysoffer a variety of options, including targeted panels that analyze genes directly linked to specific cancers by well documented scientific research, and also much larger cancer panels designed for cancer analysis and discovery.

BGI’s cancer panels are designed to identify all four classes of actionable genomic alterations, including base substitutions, insertions
and deletions, copy number alterations and selected fusions. Both tissue samples and liquid biopsy samples are supported.

BGI SENTIS™ Lung Cancer Panel

BGI’s lung cancer panel covers 11 genes with direct therapeutic implications for 20 targeted drugs, including those recommended in the latest NCCN guidelines. The panel detects all classes of genomic alterations including SNV, CNV, InDels and Fusion using routine FFPE samples, tumor tissue, DNA or peripheral blood.

BGI SENTIS™ Colorectal Cancer (CRC) Panel

Colorectal cancer is the second leading cause of cancer-related mortality in the United States. BGI uses target region capture and NGS to examine 7 genes implicated in CRC targeted therapies, including those recommended in the latest NCCN guidelines.

BGI SENTIS™ Targeted Drug Therapy Panel

BGI’s Targeted Drug Therapy Panel examines all exons and selected introns of 206 genes with direct therapeutic implications for 95 targeted therapies from a variety of sample input including fresh tissue, biopsy, FFPE, DNA and peripheral blood.

BGI SENTIS™ Cancer+ Discovery Panel

BGI’s Cancer+ Discovery Panel is designed to identify all classes of actionable genomic alterations, including SNP, CNV, InDels and Fusions, across a total of 508 cancer-related genes. Results are supported by in depth mutation analysis and pharmacogenomics information relating to 102 cancer therapeutics approved by the FDA or currently undergoing clinical trials.


Human papilloma virus (HPV) infection is associated with nearly all of cervical cancer cases (99.7%) worldwide[1] . Identification of HPV is an important tool for screening and prevention of carcinoma of the cervix. The BGI HPV Test combines self-sampling technology and genotyping assay to detect 14 most important, “high-risk” types of HPV, including HPV -16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 and 2 “low-risk” types of the virus, HPV -6, 11. In many parts of the world, HPV testing has replaced Pap smear test as the primary screening test for cervical cancer.

[1] Tanjila Rahman, Shahina Tabassum, Munira Jahan, et al.
Risk of cervical cancer associated with HPV infection among the gynae outdoor patients. Bang Med J (Khulna) 2013; 46:3-6